2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119211
    LY 97241 72456-63-4 98%
    LY 97241 accelerates the apparent rate of inactivation of transient outward K current. LY 97241 is an antiarrhythmic drug.
    LY 97241
  • HY-119232
    GSK466317A 864082-48-4 98%
    GSK466317A is a PKA inhibitor, with an IC50 of 12.59 μM. GSK466317A also inhibits GRK1, GRK2, and GRK5, with IC50s of 1000, 31.62, and 39.81 μM, respectively.
    GSK466317A
  • HY-119247
    NBI 30545 195054-99-0 98%
    NBI 30545 is a blood-brain barrier permeable CRF1R antagonist with a Ki value of 3.4 nM for the human receptor. NBI 30545 inhibits CRF-stimulated intracellular cAMP accumulation and ACTH release. NBI 30545 can be used in the research of depression, anxiety disorders and stress-related diseases.
    NBI 30545
  • HY-119256
    COR627 329221-34-3 98%
    COR627 is a GABA receptor positive allosteric modulator with the ability to enhance GABA activity. COR627 exhibits effects on GABA and baclofen stimulation in rat cortical membranes and can increase its affinity for GABA(B) receptors. In vivo experiments have shown that COR627 can enhance the sedative/hypnotic effects of baclofen at pretreatment ineffective doses.
    COR627
  • HY-119274
    BN-82451 dihydrochloride 663172-95-0 98%
    BN-82451 dihydrochloride, an orally active and CNS-penetrated antioxidant and a multitargeting neuroprotective agent, exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis.
    BN-82451 dihydrochloride
  • HY-119277
    CJB-090 dihydrochloride 595584-40-0 98%
    CJB-090 dihydrochloride is a partial agonist with activity at dopamine D3 receptors. CJB-090 exhibits partial agonist characteristics in vitro. CJB-090 elicits yawning responses only in monkeys with an extensive history of cocaine use. CJB-090 reduces the reinstatement effects of cocaine in reinstatement behaviors induced by cocaine.
    CJB-090 dihydrochloride
  • HY-119292
    AP2238 553681-56-4 98%
    AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor with Ki values for human AChE (HuAChE) and butyrylcholinesterase (BuChE) of 21.7 and 48.9 μM respectively. AP2238 blocks the pro-fibrotic interaction between the peripheral site of AChE and Aβ, and can inhibit Aβ aggregation. AP2238 can be used for the research of Alzheimer's disease.
    AP2238
  • HY-119316
    CM-414 2007971-51-7 98%
    CM-414 is a brain-penetrant phosphodiesterase 5 (PDE5) and HDAC inhibitor with IC50s of 60 nM, 91 nM, 310 nM, 322 nM and 490 nM for PDE5, HDAC6, HDAC1, HDAC3 and HDAC2, respectively. CM-414 diminishes brain Aβ and tau phosphorylation (pTau) level in Tg2576 mice. CM-414 can be used for the study of Alzheimer's disease (AD).
    CM-414
  • HY-119336
    Mebroqualone 4260-20-2 98%
    Mebroqualone is structurally categorized as a quinazolinone.
    Mebroqualone
  • HY-119348
    Nitroparacetamol 326850-30-0 98%
    Nitroparacetamol (NCX-701) is a nitric oxide (NO) donor-non-steroidal anti-inflammatory agent (NO-NSAID). Nitroparacetamol is formed by the ester linkage of Acetaminophen (HY-66005) and Nitrooxybutyroyl, aiming to combine the analgesic advantage of Acetaminophen with the organ-protective effect of nitric oxide, while expanding its anti-inflammatory activity. The analgesic spectrum of Nitroparacetamol is broader, and it is effective for painful pathological pain, and significantly reduces hepatotoxicity. Nitroparacetamol can reduce the expressions of IL-1β, TNF-α, COX-2, and iNOS.
    Nitroparacetamol
  • HY-119352
    S-2 Methanandamide 157182-48-4 98%
    S-2 Methanandamide is a potent CB1 receptor agonist, with IC50 values of 173 nM (with PMSF) and 8216 nM for CB1 and CB2, respectively.
    S-2 Methanandamide
  • HY-119363
    VU6009453 2148929-11-5 98%
    VU6009453 (compound 15q) is a brain-penetrant M4 mAChR positive allosteric modulator (PAM) with an EC50 of 383 nM. VU6009453 can be used for research on neurological diseases.
    VU6009453
  • HY-119386
    SAS-0132 1644629-60-6 98%
    SAS-0132 is a selective Sigma 2 receptor (Sig2R) antagonist (Ki: 90 nM) that can cross the blood-brain barrier. SAS-0132 is capable of regulating intracellular Ca2+ levels and modulating PGRMC1-related pathways. SAS-0132 exhibits neuroprotective activity and can improve cognitive impairment in Alzheimer's disease mice. SAS-0132 can be used in the research of neurocognitive disorders such as Alzheimer's disease.
    SAS-0132
  • HY-119398
    Lanuginosine 23740-25-2 98.27%
    Lanuginosine is an alkaloid. Lanuginosine can be isolated from the stems of Xylopia laevigata (Annonaceae) and the leaves of Magnolia grandiflora. Lanuginosine induces Apoptosis. Lanuginosine inhibits AChE (IC50: 10.9 μM). Lanuginosine inhibits Aβ aggregation. Lanuginosine exhibits anticancer activity against hepatocellular carcinoma, human promyelocytic leukemia, human chronic myeloid leukemia, melanoma, and brain tumors. Lanuginosine can be used in the research of Alzheimer's disease.
    Lanuginosine
  • HY-119399
    Salithion 3811-49-2 98%
    Salithion is an acetylcholinesterase inhibitor and neurotoxicant. Salithion binds to the active site of acetylcholinesterase to interfere with acetylcholine hydrolysis, and there is an enantioselective difference between its (R) and (S) enantiomers.
    Salithion
  • HY-119409
    Levophacetoperane 24558-01-8 98%
    Levophacetoperane (Phacetoperane free base) competitively inhibits the uptake of norepinephrin and dopamine.
    Levophacetoperane
  • HY-119426
    Dexamisole 14769-74-5 98%
    Dexamisole has R configuration that has a role as an antidepressant.
    Dexamisole
  • HY-119460
    Cuspin-1 337932-29-3 98%
    Cuspin-1 is a upregulator of Survival of Motor Neuron protein (SMN). Cuspin-1 upregulates SMN expression post-transcriptionally, and increases the phosphorylation of Erk. Cuspin-1 can be used for research of neurodegenerative disease, such as spinal muscular atrophy (SMA).
    Cuspin-1
  • HY-119461
    Capuride 5579-13-5 98%
    Capuride is an orally active sedative agent. Capuride has anticonvulsant activity.
    Capuride
  • HY-119463
    Trepipam 20012-08-2 98%
    Trepipam (Trimopam; SCH-12679) is a D1-dopamine receptor antagonist. Trepipam can reduce the self-injurious behavior in 6-OHDA-lesioned rats. Trepipam can be used in the research of epilepsy and anxiety neurosis.
    Trepipam
Cat. No. Product Name / Synonyms Application Reactivity